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SUMMARY

The Global Alliance for Genomics and Health (GA4GH) aims to accelerate biomedical advances by enabling
the responsible sharing of clinical and genomic data through both harmonized data aggregation and federated approaches. The decreasing cost of genomic sequencing (along with other genome-wide molecular assays) and increasing evidence of its clinical utility will soon drive the generation of sequence data from tens of
millions of humans, with increasing levels of diversity. In this perspective, we present the GA4GH strategies
for addressing the major challenges of this data revolution. We describe the GA4GH organization, which is
fueled by the development efforts of eight Work Streams and informed by the needs of 24 Driver Projects
and other key stakeholders. We present the GA4GH suite of secure, interoperable technical standards and
policy frameworks and review the current status of standards, their relevance to key domains of research
and clinical care, and future plans of GA4GH. Broad international participation in building, adopting, and deploying GA4GH standards and frameworks will catalyze an unprecedented effort in data sharing that will be
critical to advancing genomic medicine and ensuring that all populations can access its benefits.

INTRODUCTION
The Universal Declaration of Human Rights states that everyone
has the right to share in scientific advancement and its benefits.1,2 In order to fully deliver the benefits from genomic science

to the broad human population, researchers and clinicians must
come together to agree on common methods for collecting, storing, transferring, accessing, and analyzing molecular and other
health-related data. Otherwise, this information will remain siloed
within individual disease areas, institutions, countries, or other
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jurisdictions, locking away its potential to contribute to research
and medical advances.
The Global Alliance for Genomics and Health (GA4GH) is a
worldwide alliance of genomics researchers, data scientists,
healthcare practitioners, and other stakeholders. We are collaborating to establish policy frameworks and technical standards
for responsible, international sharing of genomic and other molecular data as well as related health data. Founded in 2013,3
the GA4GH community now consists of more than 1,000 individuals across more than 90 countries working together to enable
broad sharing that transcends the boundaries of any single institution or country (see https://www.ga4gh.org).
In this perspective, we present the strategic goals of GA4GH
and detail current strategies and operational approaches to
enable responsible sharing of clinical and genomic data, through
both harmonized data aggregation and federated approaches,
to advance genomic medicine and research. We describe technical and policy development activities of the eight GA4GH Work
Streams and implementation activities across 24 real-world
genomic data initiatives (‘‘Driver Projects’’). We review how
GA4GH is addressing the major areas in which genomics is
currently deployed including rare disease, common disease,
cancer, and infectious disease. Finally, we describe differences
between genomic sequence data that are generated for
research versus healthcare purposes, and define strategies for
meeting the unique challenges of responsibly enabling access
to data acquired in the clinical setting.
HARNESSING THE GENOMIC MEDICINE REVOLUTION
As the costs associated with human genomic sequencing
continue to decline, genomic assays are increasingly used in
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both research and healthcare. As a result, we expect tens of millions of human whole-exome or whole-genome sequences to be
generated within the next decade, with a high proportion of that
data coming from the healthcare setting and therefore associated with clinical information.4 If they can be shared, these datasets hold great promise for research into the genetic basis of
disease5 and will represent more diverse populations than
have traditionally been accessible in research; however, data
from individual healthcare systems are rarely accessible outside
of institutional boundaries.
GA4GH aims to enable the responsible sharing of clinical and
genomic data across both research and healthcare by developing standards and facilitating their uptake.6 We believe that
without such a consortium, the emerging utility of genomics in
clinical practice will be slower, more expensive, and fragmented,
with little harmonization between countries.7 GA4GH standards
(see Table 1) allow researchers to securely and responsibly access data regardless of where they are physically located. Technical standards give researchers the confidence that someone
else could reproduce their work by running the same packaged
method over the same underlying data, using the same persistent identifiers. Standards also give data providers confidence
that their data are being accessed in accordance with their
data use policies, by researchers they have authorized, without
losing control of multiple downloaded copies of the data. As a
result, data providers can enable research with the assurance
that their legal and ethical requirements are being upheld, while
researchers benefit from the use of global data resources and
tools.
As nascent genomic medicine programs emerge in many
countries, we believe that federated approaches (see Federated
access below), in addition to centralized data sharing where
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Figure 1. Matrix structure of the Global Alliance for Genomics and Health
GA4GH is a community of diverse stakeholders
from Driver Projects and other institutions working
together in the context of Work Streams. Each
GA4GH Driver Project is expected to dedicate two
full-time equivalents across at least two GA4GH
Work Streams. As foundational groups that review
all GA4GH deliverables, the Regulatory and Ethics
and Data Security Work Streams must have representation from every Driver Project. In addition
to Driver Projects, any member of the community—regardless of domain, sector, nation, or
affiliation—is invited to participate in any GA4GH
Work Stream. Supplemental information includes
details on how each of the 24 GA4GH Driver Projects intersects with the six technical Work
Streams.

feasible, are necessary to satisfy the goals of both the research
and healthcare communities. In addition, many commercial and
public organizations aim to minimize the costs and risks of the
complex technical software needed to either contribute to
genomic medicine or deliver genomic tools. A complex, multistakeholder ecosystem requires neutral and technically competent standards; these standards must be adaptable for disparate
purposes and useful for the broad set of end-users: clinical, academic, commercial, and public. Finally, standards must be
developed to intentionally support the global research community with specific attention to policies of equity, diversity, and inclusion to tangibly enable progress for all global communities.
GA4GH ORGANIZATION
GA4GH has partnered with 24 real-world genomic data initiatives (Driver Projects) to ensure its standards are fit for purpose
and driven by real-world needs. Driver Projects make a commitment to help guide GA4GH development efforts and pilot
GA4GH standards (see Table 2). Each Driver Project is expected
to dedicate at least two full-time equivalents to GA4GH standards development, which takes place in the context of
GA4GH Work Streams (see Figure 1). Work Streams are the
key production teams of GA4GH, tackling challenges in eight
distinct areas across the data life cycle (see Box 1). Work
Streams consist of experts from their respective sub-disciplines
and include membership from Driver Projects as well as hundreds of other organizations across the international genomics
and health community.
GA4GH standards development and approval process
GA4GH Work Streams and Driver Projects have identified, and
are actively developing, the technical specifications and policy
frameworks they believe to be of most relevance to enable widespread data sharing, federated approaches, and interoperability
across datasets to facilitate genomic research (see supplemental information for more details on the product development

process); the areas of focus are outlined in Box 1, with individual
products defined in Table 1 and in the 2020/2021 GA4GH Roadmap (https://www.ga4gh.org/roadmap).
Each GA4GH deliverable can be implemented on its own to
enable interoperability and consistency in a single area. However, when implemented together, they support broader activities
in the research and clinical domains and enable productive
genomic data sharing and collaborative analyses that can
leverage global datasets produced in distinct locations around
the world.
Each approved GA4GH deliverable is reviewed by a panel
of internal and external experts not involved in the product’s
development, and then by the GA4GH Steering Committee
(https://www.ga4gh.org/about-us/governance-and-leadership2/#steering). GA4GH standards are not typically accredited by a
national or international standards body, and instead follow a
model inspired by the Internet Engineering Task Force (IETF;
https://www.ietf.org) and the World Wide Web Consortium
(W3C; http://www.w3.org). This enables a flexible and rapid
response to community needs and a focus on lowering barriers
to interoperability through the development and adoption of
pragmatic standards. However, there are occasions when
certain standards benefit from a more formal accreditation process, especially when there is a direct link into healthcare usage
(see next section and Box 2).
Alignment with other standards organizations
To achieve greater international coordination and consistency of
standards development, GA4GH proactively collaborates with
other standards development organizations working in genomics, e.g., Health Level Seven (HL7; http://www.hl7.org), International Organization for Standardization (ISO; https://www.
iso.org), Open Biological and Biomedical Ontology Foundry
(OBO; http://www.obofoundry.org/). While defined work processes between GA4GH and other standards development
bodies are still under development, GA4GH has initiated several
pilot projects to explore mechanisms of collaboration. One such
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Box 1. GA4GH Work Stream focus areas
The GA4GH Work Streams are the key production teams of the organization. Each tackles a specific area in the data life cycle, as described below
(URLs listed in the web resources).

(1) Data use & researcher identities: Develops ontologies and data models to streamline global access to datasets generated in
any country9,10
(2) Genomic knowledge standards: Develops specifications and data models for exchanging genomic variant observations and
knowledge18
(3) Cloud: Develops federated analysis approaches to support the statistical rigor needed to learn from large datasets
(4) Data privacy & security: Develops guidelines and recommendations to ensure identifiable genomic and phenotypic data
remain appropriately secure without sacrificing their analytic potential
(5) Regulatory & ethics: Develops policies and recommendations for ensuring individual-level data are interoperable with existing
norms and follow core ethical principles
(6) Discovery: Develops data models and APIs to make data findable, accessible, interoperable, and reusable (FAIR)
(7) Clinical & phenotypic data capture & exchange: Develops data models to ensure genomic data is most impactful through
rich metadata collected in a standardized way
(8) Large-scale genomics: Develops APIs and file formats to ensure harmonized technological platforms can support large-scale
computing

approach is the submission of GA4GH standards to ISO’s technical committees for approval as ISO international standards.
Using a product development timeline that aligns the ISO
approval process with the GA4GH approval process, both communities are able to contribute to the development of a standard
in a harmonized manner. These efforts expand the diversity of
contributors to both organizations, leading to more robust and
internationally applicable standards. Another approach, guided
by HL7 working groups and experts, is the translation of
GA4GH standards into HL7 Fast Health Interoperability Resources (FHIR) Implementation Guides. These implementation
guides enable interoperability of GA4GH standards with clinical
systems and accelerate the use of clinical data for research.
GA4GH also aims to support and interoperate with existing
translational models, ontologies, and terminologies (e.g., FHIR,
HGVS, OMOP, PCORnet, Human Phenotype Ontology,
SNOMED CT) for clinical genetics and genomics.21–23 Before
launching a new standards development project, GA4GH Work
Streams are encouraged to complete a landscape analysis
that both defines relevant existing standards and how they will
influence the development of the new standard. Coordination
activities—such as joint meetings, shared documentation,
and process harmonization between GA4GH work and these
health standards-focused efforts—are critical for bridging the
research-clinical divide and keeping respective products
aligned. This helps prevent unnecessary proliferation of redundant standards and minimizes the development of semantically
and syntactically conflicting standards that could hamper
large-scale interoperability and lead to confusion within the
adopter community (see Box 2).
Federated approaches
Federated approaches—the ability to analyze data across multiple distinct and secure sites—is increasingly seen as an important strategy where data cannot be pooled for legal or practical
reasons. These approaches are characterized by independent
organizations hosting data in secure processing environments
(e.g., clouds, trusted research environments) while adopting

6 Cell Genomics 1, 100029, November 10, 2021

technical standards that enable analysis at scale.24 Application
programming interfaces (APIs) can be deployed to enable researchers and portable workflows to visit multiple databases
even where the data and computing environment are variably
configured.25 Tools like ‘‘identity federation’’ can facilitate even
closer integration across organizations.26–28,29
GA4GH Driver Projects and other partners are beginning to
implement cloud-based workflows built on GA4GH standards
that allow scientists to share, access, and interrogate data
stored at disparate sites around the globe. Some concrete examples of this access pattern include (1) the Data Coordination
Platform of the Human Cell Atlas, an internationally federated
compute environment for analyzing single-cell data; (2) Genomics England’s secure Research Environment for approved investigators to access the 100,000 Genomes Project dataset;
(3) the NHGRI Genomic Data Science Analysis, Visualization,
and Informatics Lab-space (AnVIL)30 and the Gen3 Data Commons, which provide cloud-based spaces for scientists to
work with large-scale genomic and genomic-related datasets
and shared tools; and (4) H3ABioNet, a bioinformatics platform
that serves data from the Human Heredity and Health in Africa
(H3Africa) network to researchers across the continent and provides containerized workflows for analysis of the data.
Because these workflows are built on interoperable standards, they allow for secure access and efficient discovery,
portability, and analysis. With more instances like these, the
global community will be able to harness the power of large
data and improve the reach of genomic medicine research.
The federation and transparency enabled by standards will
also encourage greater willingness among non-western and
other underrepresented populations to share their data, affording greater diversity in the overall data available and equity in
its impacts.
GENOMICS IN HEALTHCARE
The process of sequencing a genome is essentially the same in
any setting, but the scale and quality control of production,31 as
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Box 2. Examples of GA4GH alignment with existing standards
By aligning with existing standards, tools, and resources, GA4GH aims to minimize redundancy and the unnecessary proliferation of competing
standards. We outline three specific examples that demonstrate GA4GH efforts to align with existing standards and standards development
organizations.
Pedigree specification: The PED format is a well-known standard for exchanging pedigree information and is widely used in both research and
clinical settings (see PLINK in web resources).20 However, PED only allows for the representation of basic parent-child relationships, and does
not represent all of the data elements and relationships needed by the genomics community. Building upon this format, the GA4GH Pedigree Subgroup has mapped PED format data elements to the Pedigree data model, allowing adopters to transition to a more robust representation of family
health history without data loss and enabling compatibility with pre-existing family health history tools.
Phenopackets specification: Phenopackets, a standard for case-level phenotypic data exchange, can be compared to a hierarchical structure of
‘‘slots’’ that can be populated with ontology terms and other data. In order to maximize utility of computational analyses, these slots are compatible
with any pre-existing terminologies or ontologies, such as the Human Phenotype Ontology for human disease phenotypes, NCI Thesaurus for cancer, LOINC for laboratory results, and MONDO for diseases. The modular design of the standard also enables interoperability with complementary
GA4GH deliverables, like Pedigree and the Variation Representation Specification (VRS), by integrating them within the structure of the
phenopacket.
Genomic variation: The GA4GH Variation Representation Specification (VRS) and Variant Annotation (VA) framework were developed to address
the diverse methods used to access reference genome sequence and genomic annotation (e.g., genes, variation, regulatory regions, expression).
Associated metadata can often be unstructured. VRS and VA aim to enable the provision, sharing, and computational representation of genomic
variation information in a way that is unambiguous and semantically rigorous. These specifications are developed with bidirectional feedback with
the standards of the health level 7 (HL7) clinical genomics working group, which supports the reporting of clinical genomic test results and related
information with electronic health records (EHRs). Alignment between these specifications is a critical step toward supporting data exchange and
system interoperability across the clinical-translational-research spectrum.

well as the regulation and dissemination of the resulting data,
can be quite different in healthcare compared to research.32,33
‘‘Research genomes’’ contain de-identified data and therefore
are often openly shared with other researchers, including for
funding and publishing requirements (for NIH policy, see web resources), frequently with managed access, e.g., via the European Genome-phenome Archive (EGA), the Japanese Genotype-phenotype Archive (JGA), or the database of Genotypes
and Phenotypes (dbGaP). Researchers worldwide will draw on
these openly shared genomic datasets for their own studies,
increasing the amount of knowledge derived from each
genome.34 However, while such research genomes are more
readily available, these datasets usually do not include the type
or extent of longitudinal, standardized, or interoperable clinical
data needed for genomic medicine.35
Healthcare-based research and testing have an entirely
different financial, legal, and social landscape, with the structure,
provision, and regulation varying by country, covering the full
spectrum from state-run to private schemes.7 In each system,
the cost of an assay in healthcare—genomics included—is often
considered in light of its benefits to the health of an individual and
cost effectiveness within the healthcare system.36 In theory, if a
genomic assay demonstrates clinical utility for a specific application within a healthcare system—especially if it is cost effective—the only limit to its deployment is the number of patients
who will potentially benefit. In practice, however, there are logistical, financial, regulatory, educational, scientific, and clinicalbased hurdles to overcome before a genomic test becomes a
routine clinical offering. In addition, barriers to healthcare access
will likely remain impediments to large-scale implementation in
many countries.
The current case for implementing genomics in healthcare
can be presented in four broad disease areas: rare disease, cancer, common/chronic disease, and infectious disease. In the
following sections we outline the case for healthcare-funded

sequencing in each disease area. We also highlight challenges
to implementation in each area and GA4GH deliverables aimed
at overcoming these issues.
Rare disease
Arguably, the rare disease space has seen the most successful deployment of genomics in healthcare, with many reporting
diagnostic rates of at least 20%–30%, and health economic
studies demonstrating cost-effectiveness and diagnostic utility.36–41 Clinical geneticists have used single-gene or small
gene panel tests since the early 1990s to support diagnosis
and some treatment decisions for many of these diseases.
The cost of assaying broader genomic regions—including
exome and genome sequencing—has fallen considerably,
with a substantial impact on rare-disease diagnosis and discovery research.42,43 However, with more than 10,000 rare
diseases44 affecting more than 300 million patients worldwide,45 diagnosing and discovering treatments for many of
these diseases has been challenging. As such, the rare disease community has embraced data sharing in order to facilitate global knowledge exchange and improve patient diagnostic rates, understand disease progression, and augment
care strategies.41
To further enable progress, clinical and research laboratories
and health systems must support several key activities to effectively identify, diagnose, and eventually treat the genetic causes
of rare disease: (1) aggregate genomic and phenotypic data,
needed for discerning population allele frequencies in disease
and non-disease populations and implicating new genes in
rare disease; (2) catalog the validity of gene-disease associations using consistent annotation models and terminologies;46
(3) collectively build knowledge bases to understand variant
pathogenicity; (4) define the natural histories of rare diseases
to predict disease progression and enable a foundation upon
which to develop clinical trials; and (5) monitor treatment efficacy
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of emerging therapeutics. GA4GH standards and policies
already enable and will continue to build upon these activities.
For example, the Matchmaker Exchange—a rare disease gene
discovery platform which has benefited from GA4GH guidance
on API-based data exchange formats as well as consent47 and
data security policies48,49—illustrates the power of bringing
practicing clinicians and researchers together, as cases from
across the globe are necessary to build evidence to confirm
new gene-disease relationships.48
GA4GH promotes knowledge sharing in ClinVar, a database
which has accelerated improvements in variant classification
across the clinical laboratory community.50 Additional methods
are now being deployed to move beyond manual submission
of variant classifications to a centralized database; such advances will enable more timely access to siloed laboratory
knowledge and evidence-based variant classification. Realtime sharing with ClinVar—facilitated by APIs and with entries
linked to rich, case-level data—will be needed to scale our understanding of the more than 750 million variants so far identified
in the human genome (e.g., within gnomAD; https://gnomad.
broadinstitute.org). The Variation Representation (VRS)18 and
Variant Annotation (VA) specifications aim to support the exchange of variant data, Phenopackets and Pedigree representation to support the use of standardized clinical and family history
data, as well as new APIs (e.g., Beacon v2 API and Data Connect
API) to enable the identification of data for further access and
analysis. The aim is for these standards to support a more global
and federated approach to rare disease data and knowledge
sharing that will be critical to advancing diagnosis and treatment
of rare diseases.
Cancer
One in five men and one in six women worldwide will have a
cancer diagnosis in their lifetime.51 This risk is 2- to 3-fold greater
in higher-resource countries,51 with estimates as high as one
in two people in the UK for example.52 An altered somatic
genome is a consistent hallmark of cancer, often associated
with specific pathogenic mutations.53 In some individuals with
hereditary cancer syndromes, germline variants can disrupt cancer-related pathways and increase the risk of developing a ‘‘heritable’’ malignancy.54–56 Characterizing a cancer by sequencing
a patient’s tumor genome alongside their germline genome
has resulted in profound insights into molecular mechanisms
of malignant transformation and discovery of potential therapeutic targets.57,58 Tumor/normal sequencing has demonstrated
applications in disease monitoring59 as well as diagnosis,60
prognosis,61 and therapeutic response prediction,62 both at
initial presentation63 and disease recurrence.64
Applying cancer genomics in the clinic is more complicated
than that for rare diseases. For cancer patients, treatment strategy time frames are commonly measured in weeks and incorporating genomic information within such an urgent turnaround
time is logistically challenging to integrate into clinical decision
making.65 Additionally, while the use of genomics for diagnosis
and improved symptom management can lead to substantial improvements for rare disease patients and their families, application of genomics in cancer treatment is more complex and may
include dual assessment of both somatic and germline genomes
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to determine heritable cancer risk and the assessment of the
evolving tumor genome due to changing selective pressures in
response to targeted therapies. Cancer genomic information is
most useful if it informs treatment options, yet development of
systems that match patients to appropriate clinical trials would
be needed to fully realize the benefits of genomic tumor data
where estimates of clinical trial enrollment in patients with cancer
stands at 8%.66 Genomic information is increasingly important
in clinical decision making through routine clinical sequencing
assays and molecular tumor boards.67 The heterogeneity of cancer as a disease—of each individual tumor and of any concurrent
or subsequent manifestation, such as metastasis or recurrence—adds many layers of complexity to genomic analysis.68
To address this complexity, it is important to analyze somatic
and germline variation data together to understand their contribution to cancer risk.69
Most of the same standards and workflows important for rare
disease apply to tumor sequencing, including data storage and
compression standards (e.g., CRAM), variation representation
(e.g., VCF and VRS), analysis (e.g., cloud-based workflows),
and linkage to patient records (e.g., Phenopackets). However,
discovery of oncogenic driver mutations also requires significant
coordination and standardization to track outcome data (e.g.,
progression and response to treatment), a key element in determining the clinical significance of variation found in cancer patients.70 As such, many groups have created knowledge bases
to annotate cancer genomic variation associated with evidence
of pathogenicity or relevant treatment options; however, these
knowledge bases can have limited levels of interoperability. In
2014, a GA4GH task team launched the Variant Interpretation
for Cancer Consortium (VICC), which standardizes and coordinates clinical somatic cancer curation efforts and has created
an open community resource to provide the aggregated information.71 Moving forward, major oncogenomic resources are now
working with GA4GH on the harmonization of variant interpretation evidence, through refinement and adoption of standards
such as the Beacon API, the Data Use Ontology (DUO),9 VA,
and VRS. Additionally, these standards are being implemented
across multiple GA4GH Driver Projects (see Table 2) that capture
genomic data and/or diagnostic variant interpretation across the
longitudinal evolution of cancer.
Common/chronic disease
‘‘Common disease’’ is a catchall phrase describing a vast spectrum of diseases that have complex environmental and genetic
etiologies. Accurate prediction of common diseases from genetics has been a topic of study since the inception of human genetics, yet genomic information is still not widely used in clinical
practice for this purpose. The discovery of a large number of genetic susceptibility loci (polygenic architecture) supported the
common-disease common-variant hypothesis72 and has led to
the generation of polygenic risk scores summarizing common
disease risk.73 Studies are now beginning to demonstrate the
clinical benefits of applying polygenic risk scores in practice
through stratification of the population for deploying disease
management strategies.74–76 As the assay of choice moves
from genotype arrays to sequencing, there will be integration between common disease and rare disease applications; this is
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already the case for certain diseases such as susceptibility to
breast cancer75 or heart disease.77 When such genomic information can be used clinically for common diseases, it will be more
justifiable to sequence entire populations. Population-scale
sequencing is in place already in some countries (e.g., Iceland)
and is likely to become more commonplace in the next two
decades.
To support the discovery of the genetic causes and contributors to common disease across all populations, researchers
must be able to identify and access aggregated data from
large-scale cohort population studies from diverse backgrounds, carried out by multiple distinct sites such as biobanks
in the UK (UK BioBank, Generation Scotland), China (China Kadoorie Biobank), the US (NIH All of Us Research Program), and
Japan (Tohoku Medical Megabank, Japanese BioBank); and
whole population cohorts in Iceland (deCODE), Estonia (Estonian
Genome Project), and Finland (FinnGen). Doing so requires the
data to be harmonized across all sites using common data
models and terminologies. Furthermore, since genomic datasets
of this scale are too large to download and manipulate at individual sites, researchers must be able to bring analytical tools to the
data, regardless of their location.
Protocols are needed to deploy these tools consistently and
effectively across distinct federated sites. GA4GH products support this critical type of biological study across the typical
research life cycle from data discovery to analysis: (1) identify
and access datasets relevant to a disease study (e.g., GA4GH
Passports, DUO, multiple data discovery APIs), (2) access secure
genotype and phenotype information on patients with related
traits (e.g., Phenopackets, Data Repository Service [DRS] API,
VRS, VA), and (3) remotely run analytical methods on data of interest (e.g., Task Execution Service [TES], Workflow Execution
Service [WES] API, htsget API12), avoiding the need for inter-jurisdictional transfers and disparate regulatory requirements.
Infectious disease
Genomics can be used to identify the infectious agents of disease with more confidence and precision than ever before, and
at increasing speed, allowing treatments that can quickly resolve
infections78–80 as well as identifying the evolution of new species
that may evade antibiotics, antivirals, and vaccines. The main
challenges to deployment of genomics in infectious disease
care are managing cost and logistics, tracking disease progression and its characterization, achieving precise phenotypic prediction (e.g., antibiotic resistance), and harmonizing historical
knowledge bases from non-genomic-based assays to integrate
with contemporary genomic tests. The COVID-19 pandemic
tested this infrastructure, with diagnostic testing becoming
widespread, viral genomic sequencing enabling tracking of
strains, and human genome sequencing of symptomatic individuals contributing to a better understanding of the basis of
COVID-19 disease severity.81
Infectious disease genomic research and surveillance primarily rely on sequencing bacterial and viral pathogens and the organisms in which they are carried and transmitted. These genomes vary greatly in size, content, and associated metadata,
so the standards and APIs created for human genomic data
may be insufficient for infectious disease data. However, while
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the specific data standards needed to advance pathogen genomics differ from those in human genomics, there is still considerable overlap in the mechanics of sharing the data.
Through a variety of strategic alignments with organizations
such as the Public Health Alliance for Genomic Epidemiology
(PHA4GE; https://pha4ge.org/), the International COVID-19
Data Alliance (ICODA; http://www.icoda-research.org), and the
European COVID19 data portal (http://www.covid19dataportal.
org), GA4GH is working to ensure that the species-agnostic elements of genomic data sharing standards are transferred into the
infectious disease community. In addition, some GA4GH standards have begun to explore how they should adapt to support
infectious disease data; for example, the Phenopackets standard was improved to support case-level presentation for infectious diseases in 2020 in response to the COVID-19 pandemic. In
addition, recently launched initiatives such as large-scale tuberculosis sequencing in several countries,82 rapid identification of
Ebola and Zika virus strains,83 and tracing hospital outbreaks using genomics84,85 demonstrate a vibrant, functional interface between research, public health institutions, and clinical practice.
CHALLENGES TO SECONDARY USE OF CLINICALLY
ACQUIRED DATA
We envision the global clinical and research communities collaborating seamlessly in the context of practicing healthcare86,87 to
enable a true ‘‘learning healthcare system’’ (LHS). The LHS
concept has existed for over a decade;88,89 however, implementation is still in its infancy, facing several barriers.90 Some useful
implementations are found across medicine,91–94 including
genomic medicine.95 Increasing numbers of institutions and
countries have begun biobanks, in many cases connected to
their healthcare system (see Common/chronic disease above),
providing fertile grounds on which to bring healthcare data—
including clinical genomic data—into research.
To enable these efforts to reach their full potential, disparate
systems must be able to share genomic and clinical data,
requiring the community to overcome key challenges, particularly in the areas of infrastructure development, patient and
physician incentives, ethics and regulation, privacy and security,
and socio-cultural expectations (see Box 3). We believe these
challenges can be overcome—but only if the genomics and
healthcare communities commit to broad-based advocacy and
coordinated efforts worldwide.
This has already been successfully modeled through the Clinical Genome Resource (ClinGen; a GA4GH Driver Project), where
healthcare providers, clinical laboratory staff, and researchers
work together to develop standards for gene and variant curation, share underlying evidence, and then apply that evidence
through a consensus-driven process to classify genes and variants which are made freely accessible to the broader community
to support both research and clinical care.96,97
Developing clinical data standards
Much of the clinical data contained within healthcare are not encoded in a standardized format.98 Multiple electronic health record (EHR) vendors exist today and are highly proprietary in their
technical structures, making standardization across EHRs and
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Box 3. Major barriers hindering secondary use of clinically acquired data
Here we outline some of the major challenges to achieving the broad goal of responsible sharing of genomic and related health data. This includes
setting up the infrastructure to support the flow of data from clinical practice into research, as well as establishing data-access and accountability
mechanisms that are appropriate to research settings. These need to be consistent with the legal frameworks of the healthcare setting, and respectful of the rights of the individual data donor including their privacy, the security of their data, and their autonomy with regard to research participation.

1.
2.
3.
4.
5.
6.
7.

Inconsistency and lack of version control in data-generating pipelines
Lack of dataset interoperability due to disparate data models and terminologies
Inadequate infrastructure for ingesting and storing data
Difficulty or lack of resources for enabling access to data
Insufficient consent for data sharing and lack of resources to support the consent process
Data privacy and security issues, as well as real and perceived regulatory issues
Challenges to ensuring patients understand how their data are used and have sufficient autonomy around data sharing participation
8. Differences in priorities, experiences, and trust levels concerning data sharing between different population groups and stakeholders
9. Lack of incentives in the clinical care system for prioritizing data sharing and research
10. Lack of data-sharing mandates

with downstream research systems difficult. Although data recorded in EHRs often use standardized clinical terminologies
(e.g., ICD, SNOMED CT), the intent of these systems is generally
to present clinical information on individuals to healthcare providers and, in some regions, facilitate billing practices. This presents a challenge for secondary users, where it is difficult to
make accurate, population-scale conclusions, often requiring
extensive efforts to understand practices and generate useful
research data.99 In order to promote adoption of standardized
formats in research and ultimately within EHRs, GA4GH is developing standardized information models (e.g., Phenopackets,
Pedigree) to describe clinical phenotypes and family histories.
Standardizing the representation of phenotype and pedigree information will allow patients, care providers, and researchers to
share this information more easily between healthcare and
research systems and enable software tools to use this information to improve genome analysis and diagnosis.
Incentivizing and facilitating data sharing in healthcare
Resource limitations for healthcare providers and patients also
impact their ability to share valuable clinical data. Some healthcare institutions (e.g., NHS England [https://www.england.nhs.
uk/genomics/nhs-genomic-med-service], Dana-Farber Cancer
Institute [http://www.dana-farber.org/for-patients-and-families/
becoming-a-patient/preparing-for-your-first-appointment/check
list-for-new-adult-patients], Danish healthcare100) have built
layered consent procedures into the regular routine of medical
practice.101 Others support parallel biobanking efforts to separately consent patients for research.102–106 Still others have built
this into their operations as an inherent part of the healthcare
system.100 Further incentives can be built if providers can experience the direct benefits of research. For example, the clinical
laboratory genetic testing industry largely participates voluntarily
in data sharing through ClinVar, in part because they directly
benefit from accurate variant interpretation.50,107,108 Several laboratories also joined when the US insurance industry began
requiring submission as a condition of test reimbursement.109
However, despite progress in the sharing of variant knowledge,
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additional incentives and infrastructure are needed to support
access to case-level results (e.g., variants interpreted for a patient indication) as well as full sequencing data, along with rich
clinical phenotypes. Currently, most genetic test results are returned through PDF-based reports or accessed through external
portals outside the medical system. Although standards exist for
the exchange of genetic test results (see, for example, HL7’s
guide in the web resources),110 robust standards that capture
highly detailed, discrete genomic data are still under development. Adoption of those standards has been motivated by the
implementation of downstream clinical decision support,111–113
but more incentives and infrastructure will be needed.
To date, GA4GH has worked on maintaining and evolving
standardized file formats for raw and annotated genomic data
(SAM, BAM, CRAM, VCF/BCF); individual variant representation
and interpretation (VRS, VA); and transmission of individual
phenotype data and interpreted results (Phenopackets), all of
which are critical for the evolving use of genomics in healthcare
systems—particularly clinical laboratory workflows to share
genomic data and genetic testing results. Future areas of development include better representation of structural variants, unambiguous representation of complex multi-allelic loci, and
research into new, more scalable formats for storing and
exchanging genetic variation. Population-scale sequencing programs in which healthcare systems share clinical genomic data
for research are unlikely to allow large-scale aggregation of
data to migrate beyond national boundaries, but federated analysis—in which analytical algorithms or queries are brought to the
data in its location without data egress—is feasible and is a major
area of focus of GA4GH’s standards development.
Ethics and regulation
Ethical considerations for patients and populations, together
with responsible regulation, are essential for healthcare-funded
genomics, which involves complex national regulation and
legislation. Different countries and institutions have individual
values and policies that relate to allowing access to personal information, with some embracing more open regulatory norms
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Box 4. GA4GH Regulatory & Ethics Toolkit
The GA4GH Regulatory and Ethics Work Stream (REWS) develops ready-to-use policy guidance to support responsible, international genomic and
health-related data sharing. Here, we list central components of the GA4GH Regulatory & Ethics Toolkit. The REWS also reviews all GA4GH technical standards for any regulatory or ethics issues that may be relevant.
Policy Frameworks: GA4GH has developed five policy guidance documents (or ‘‘Frameworks’’) that build on the Framework for Responsible
Sharing of Genomic and Health-Related Data, each aiming to address a specific area of responsible data sharing:
d

d

d

d

d

Consent Policy Framework: describes how to maximize responsible and respectful international data sharing through the
design of consents for prospective data collection and through the assessment of existing consents for retrospective data
sharing (https://www.ga4gh.org/wp-content/uploads/GA4GH-Final-Revised-Consent-Policy_16Sept2019.pdf)
Data Privacy & Security Policy Framework: provides principled and practical guidance for processing data in a way that protects and promotes the security, integrity, and availability of data and services, and the privacy of individuals, families, and communities whose data are processed (https://www.ga4gh.org/wp-content/uploads/GA4GH-Data-Privacy-and-Security-Policy_
FINAL-August-2019_wPolicyVersions.pdf)
Ethics Review Recognition Policy Framework: provides essential elements for the ethics review process of multi-jurisdictional research involving health-related data so as to foster recognition of extra-jurisdictional ethics reviews and efficient and
responsible health-related data sharing (https://www.ga4gh.org/wp-content/uploads/GA4GH-Ethics-Review-RecognitionPolicy.pdf)
Cloud Privacy & Security Policy Framework: provides principled and practical best practices for sharing data in a way that
protects and promotes the confidentiality, integrity, and availability of data and services, and the privacy of individuals, families,
and communities whose data are shared (https://www.ga4gh.org/wp-content/uploads/Privacy-and-Security-Policy.pdf)
Policy Framework for Clinically Actionable Genomic Research Results: provides a reference point for managing the return
of clinically actionable research results that recognizes the importance of the accountability and transparency of genomic researchers toward participants (https://www.ga4gh.org/wp-content/uploads/2021-Policy-on-Clinically-Actionable-GenomicResearch-Results.pdf)

Model Consent Clauses: A typology of model consent clauses that aim to assist researchers in the drafting of interoperable consent forms and
ensure they use language that matches cutting-edge GA4GH international standards. A typology of clauses has been developed for genomics
research (https://www.ga4gh.org/wp-content/uploads/Consent-Clauses-for-Genomic-Research.docx.pdf), familial consent (https://www.ga4gh.
org/wp-content/uploads/Familial-Consent-Clauses-6.pdf),114 pediatric consent (forthcoming), and rare disease (https://bmcmedethics.
biomedcentral.com/articles/10.1186/s12910-019-0390-x/tables/3). Additional typologies are forthcoming for large-scale initiatives and clinical
whole-genome sequencing.
Machine Readable Consent Guidance (MRCG): The MRCG provides instructions for researchers to integrate standard data-sharing language
into consent forms in a way that can be translated into a computable language. Machine-readable consent language can be attached to datasets
and stored in their descriptive data using DUO terms. Researchers can then search for datasets that have been consented for their research purposes (https://www.ga4gh.org/wp-content/uploads/Machine-readable-Consent-Guidance_6JUL2020-1.pdf)
Data Access Committee Review Standards (DACReS): DACReS is a set of procedural standards for data access committees that facilitate consistency, effectiveness, and robustness of reviews for data access requests to genomic and health-related data.
Engagement Framework: This framework enables researchers and others to robustly design engagement with various public and patient audiences implicated in genomic data sharing. Through reflexive questions centered around themes of fairness, context, heterogeneity, and the recognition of tension, the framework facilitates critical inquiry into stakeholder engagement (https://www.ga4gh.org/wp-content/uploads/GA4GH_
Engagement-policy_V1.0_July2021-1.pdf).
GDPR Briefs: These monthly briefs answer important questions about the impact of the European General Data Protection Regulation on various
aspects of international health research and genomic and health-related data sharing. (https://www.ga4gh.org/genomic-data-toolkit/regulatoryethics-toolkit/gdpr-forum/).

and systems on data collection, access, and sharing, and others
being more restrictive. Nevertheless, most systems have some
mechanism for researchers to access both research and clinical
data. The GA4GH Regulatory and Ethics Work Stream (REWS)
develops ready-to-use policy guidance to support responsible,
international genomic and health-related data sharing. In Box
4, we list central components of the GA4GH Regulatory & Ethics
Toolkit, including policies, consent tools, and data access guidance. The REWS also reviews all GA4GH technical standards for
consideration of any regulatory or ethics issues that may be
relevant.
The first REWS product was the GA4GH Framework for
Responsible Sharing of Genomic and Health-Related Data,115
which is built on the human right to benefit from scientific prog-

ress and its applications, as well as privacy, non-discrimination,
and procedural fairness. It provides guidance for the responsible
sharing of human genomic and health-related data, including
personal health data and other types of data that may have predictive power in relation to health. The Framework has now been
translated into 14 languages and has been used to inform local
data sharing approaches around the globe, including, for
example, the World Economic Forum,116 the Academy of Science of South Africa,117 DNA.Land, Health Data Research
UK,118 and the Horizon-2020 CORBEL project.119 Keeping the
fundamental human right to benefit from science at the heart
of clinical and genomic data sharing ensures a universal
approach to balancing the benefits and potential risks. We
believe that most healthcare system actors can ultimately
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participate in responsible, worldwide data sharing while remaining compliant with applicable laws and institutional policies.
Privacy and security
Federating large volumes of sensitive clinical and genomic data
across internationally distributed virtual computing environments presents formidable challenges in assuring data integrity,
service availability, and individual privacy. Some of these challenges call for innovative application of well-established security
standards, frameworks, and protocols—such as identity federation on a global scale—and some GA4GH standards already do
so (e.g., crypt4GH, Authentication & Authorization Infrastructure
[AAI] / Passports). Another crucial challenge is to enable secure,
privacy-preserving federated analysis, wherein researchers can
extract information without having to transfer raw data. This evolution is key to foster inter-institutional and international collaboration and will be a strong incentive to improve ontology homogeneity. Several technical solutions are available, either based
on hardware devices or on software algorithms. The former are
computationally efficient, but require trusting a vendor and
are prone to side-channel attacks. The latter are computationally slower, but are mathematically proven and are a better
response to GA4GH expectations. Recent results have demonstrated the effectiveness of a software-based approach (a
combination of homomorphic cryptography and secure multiparty computation called ‘‘Multi-party Homomorphic Encryption’’ or MHE); these approaches have been positioned with
respect to the GDPR.120,121 One of the major strengths of MHE
is that partial aggregates can be considered to be anonymized
and not just pseudonymous, in the sense of GDPR, and thus
potentially obviating the need for data transfer and use agreements (DTUAs).
Societal challenges
Societal challenges of allowing access to genomic data within
the healthcare ecosystem include maintaining public trust,
overcoming differences in objectives and methods between
research and healthcare, and breaking down unproductive divides between disciplines. Our vision for healthcare data ecosystems is one in which vetted researchers around the world
can, with appropriate oversight and policy enforcement, gain
access to human health data for the benefit of patients.
GA4GH has defined the core elements of responsible data
sharing, including transparency, accountability, recognition,
and attribution as well as sanctions for misuse which form a
framework to respect and maintain the trust of participants.122
In particular, the GA4GH Engagement Framework (see Box 4)
further assists researchers in designing and understanding
engagement with public, patient, and participant stakeholders
through the central themes of fairness, context, heterogeneity,
and the recognition of tensions. Through the implementation
arm of GA4GH, the Genomics in Health Implementation Forum
(https://www.ga4gh.org/implementation) described below and
other engagement efforts, GA4GH is tackling the broader societal implementation issues including education and engagement of the public, healthcare providers, and regulators in order to build trust within the community. The GA4GH ‘‘Your
DNA, Your Say’’ survey, an effort to gather international public
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attitudes toward genomic data sharing, has provided an evidence base for understanding which factors are important to
maintaining public trust in the generation and sharing of
genomic data, as well as how concerns differ according to geography.123,124 These findings help ensure that GA4GH’s work
can enhance the public trust in a global context upon which the
future of genomics depends.
CONNECTING STANDARDS FOR IMPLEMENTATION
With more than 30 GA4GH standards approved, and dozens of
production-ready implementations of those standards deployed
around the world, GA4GH is now shifting its focus toward
demonstrating how standards can work together to provide
seamless support of genomic activities. Interconnected standards that are compatible and interoperable with each other
and are hardened for real-world use will enable solutions for
federated analyses across platforms and use cases. To drive
this effort, GA4GH has established the Federated Analysis System Project (FASP), which aims to demonstrate how GA4GH
APIs, when used in concert, can support real-world, scientific
use cases (see https://www.ga4gh.org/genomic-data-toolkit/
2020-connection-demos/). A key outcome of FASP is a series
of scripts that represent working examples of clients accessing
real-world GA4GH-compatible services to solve a spectrum of
challenges across the search-access-analyze workflow. The
scripts illustrate how these services have adopted GA4GH standards to solve challenges, such as dataset discoverability and
controlled data access, in order to drive larger scale and more
powerful analyses.
By developing working implementations of GA4GH standards
that are pressure tested in real world scenarios, the FASP team
has identified specific areas of improvement within the standards. As a result of this work, new features will be added to existing GA4GH specifications to further facilitate secure, realworld federated data sharing and analysis. Most notably, the
group is working toward a standardized solution for using a
GA4GH Passport to access a controlled access dataset from a
Data Repository Service (DRS), while fulfilling robust security
requirements, such as preventing escalation of privilege. These
efforts will be critical to support access to valuable datasets
across the globe.
GA4GH Starter Kit
To date, GA4GH has primarily focused on overcoming the challenges of enabling interoperability within new initiatives built on a
foundation of cloud infrastructure. However, an additional—and
potentially more significant—challenge is bringing high-performance computing (HPC) infrastructures that are not already
focused on cloud interoperability into the federated network envisioned by this community.
While more ambitious goals are on the horizon for connecting
and extending GA4GH standards (e.g., discovery of datasets;
matching requests, analyses, and datasets; describing phenotypes; reporting on variants), FASP has shown through its realworld demonstrations of access across distributed but interoperable datasets that the initial groundwork for federated analysis
is now in place. The Data Repository Service (DRS) allows data
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custodians to make controlled access data available at multiple
sites; the Workflow Execution and Task Execution Services
(WES & TES) allow researchers to encapsulate and run analyses
on those data; and AAI and Passports allow for federated authorization and authentication, streamlining the data access process for both researchers and data custodians.
In 2021, GA4GH has begun to develop the GA4GH Starter Kit,
a set of open source reference implementations (for example,
code bases that demonstrate the standards working in practice),
to help ensure existing HPC environments can interoperate with
the wider GA4GH network. These resources consist of ‘‘plugand-play’’ code that any institution (cloud-based or HPC) can
use to quickly achieve GA4GH compatibility and will facilitate
the progressive movement of established large-scale systems
toward interoperability. In addition, a testing suite will be developed to ensure deployments of both reference and non-reference implementations are compliant to their respective
GA4GH specifications.
Genomics in Health Implementation Forum
Once standards have been piloted in real-world Driver Project
settings and shown to enable true federated analysis in FASP,
they can begin to be promoted more broadly in the research
and clinical genomics communities. Launched in 2020, the Genomics in Health Implementation Forum (GHIF) brings together
a group of national-scale genomic data initiatives to share resources, experiences, and best practices for implementing
GA4GH standards, as well as broader experience in rolling out
national and international data sharing activities. GHIF aims to
support more accurate data interpretation and disease diagnosis plus other innovative solutions across healthcare through
global cooperation in data sharing and clinical implementation
of genomics.
Broad uptake of GA4GH standards among GHIF members—
which include both GA4GH Driver Projects as well as other national and multi-national initiatives (see https://ga4gh.org/
implementation for full list)—will provide strong evidence that
GA4GH standards are supporting the community’s actual data
sharing needs.
Implementation of GA4GH policies and standards throughout
the scientific and healthcare communities will allow researchers
to access data across the globe—a critical step toward
answering otherwise impenetrable questions about disease
and basic human biology. As the volume of genomic and
health-related data grows exponentially around the world, researchers, clinicians, and bioinformaticians have a responsibility
to make that data appropriately accessible and to use it to realize
benefits for all humans everywhere. The promise of genomic
medicine lies at a crossroads that depends on harmonization
across the global community to significantly enhance human
health and medicine. We believe that GA4GH, by embracing
collaborative innovation and knowledge exchange, is well
poised to meet this challenge.
SUPPLEMENTAL INFORMATION
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URL

Type

Target user

Purpose

Identify and access datasets relevant to a disease study
https://app.swaggerhub.
com/apis/ELIXIR-Finland/
ga-4_gh_beacon_api_
specification/1.0.0-rc1

API

data custodians, researchers
(via research infrastructures),
identity provider services

The Beacon protocol defines an open standard for genomics data
discovery. It provides a framework for public web services
responding to queries against genomic data collections, for instance
from population-based or disease-specific genome repositories.
Beacon is designed to (1) focus on robustness and easy
implementation, (2) be maintained by individual organizations and
assembled into a federated network, (3) be general-purpose and able
to be used to report on any variant collection, (4) provide a boolean (or
quantitative) answer about the observation of a variant, and (5) protect
privacy, with queries not returning information about single
individuals. A new version of the API will include support for more
granular control based on a user’s identity authorization and will
enable discovery of cohorts, cases (patients), biological samples, and
genomic variants and associated knowledge. More details can be
found on the Beacon Project website.

Data Connect

https://github.com/ga4ghdiscovery/data-connect

API

data custodians, researchers,
and API & tool developers

Data Connect is a specification for discovery and search of
biomedical data, which provides a mechanism for describing data
and its data model, and for searching data within the given data
model.
The primary container for data in Data Connect is the table. Tables
contain rows of data, where each row is a JSON object with key/value
pairs. The table describes the structure of its row objects using JSON
Schema (https://json-schema.org/). Row attributes can take on any
legal JSON value, e.g., numbers, strings, booleans, nulls, arrays, and
nested JSON objects.
The API supports browsing and discovery of data models and table
metadata, listing table data, and optionally searching table data using
arbitrarily complex expressions including joins and aggregations. The
query language is SQL with domain-specific functions to facilitate
informative typing of the result fields. Data publishers can wrap
existing data storage and retrieval systems in the Data Connect API or
may choose to publish data directly as static files in the Data Connect
JSON format.
Data consumers can use Data Connect via graphical data discovery
and exploration built upon the API, via command line tools
(interactively or in batch workflows), and directly as an API in custom
analysis programs. More information can be found in the specification
(https://github.com/ga4gh-discovery/data-connect/blob/master/
SPEC.md).
(Continued on next page)
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Beacon API8
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Continued
URL

Type

Target user

Purpose

Data Use
Ontology9

http://purl.obolibrary.org/
obo/duo.owl

Data Model /
Ontology

data custodians, researchers,
DACs

The Data Use Ontology (DUO) is a hierarchical vocabulary of terms
describing data use permissions and modifiers, in particular for
research data in the health/clinical/biomedical domain. The GA4GH
DUO standard allows large genomics and health data repositories to
consistently annotate their datasets, ensuring a shared, machine
readable, representation of data access conditions, and making them
automatically discoverable based on a researcher’s authorization
level or intended use.
Reference implementations are available at
d Broad’s FireCloud - Data Library
d Broad’s DUOS (Data Use Oversight System) - Data Catalog
d European Genome-Phenome Archive.
DUO is based on the OBO Foundry principles (http://www.
obofoundry.org/principles/fp-000-summary.html) and developed
using the W3C Web Ontology Language. DUO can be browsed online
via the Ontology Lookup Service or Ontobee. It has been registered
with the OBO Foundry (http://obofoundry.org/ontology/duo.html).

GA4GH
Passports10

https://github.com/ga4ghduri/ga4gh-duri.github.io/
blob/master/researcher_
ids/ga4gh_passport_v1.md

API / Data
Model

data custodians, researchers,
DACs, clinicians, API and tool
developers

The GA4GH Passport specification aims to support data access
policies within current and evolving data access governance
systems. This specification defines Passports and Passport Visas as
the standard way of communicating a user’s data access
authorizations based on either their role (e.g., researcher), affiliation,
or access status. Passport Visas from trusted organizations can
therefore express data access authorizations that require either a
registration process (for the Registered Access data access model11)
or custom data access approval (such as the Controlled Access
applications used for many datasets).

Service Info

https://github.com/ga4ghdiscovery/ga4gh-serviceinfo

API

API and tool developers

Service discovery is at the root of any computational workflow using
web-based APIs. Traditionally, this is hard-coded into workflows, and
discovery is a manual process. Service Info provides a way for an API
to expose a set of metadata to help discovery and aggregation of
services via computational methods. It also allows a server/
implementation to describe its capabilities and limitations. Serviceinfo is described in GA4GH OpenAPI specification, which can be
visualized using Swagger Editor (https://editor.swagger.io/?
url=https://raw.githubusercontent.com/ga4gh-discovery/
ga4gh-service-info/develop/service-info.yaml).

ll

(Continued on next page)
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https://github.com/ga4ghdiscovery/ga4gh-serviceregistry

API

API and tool developers

Service registry is a GA4GH service providing information about other
GA4GH services, primarily for the purpose of organizing services into
networks or groups and service discovery across organizational
boundaries. Information about the individual services in the registry is
described in the complementary Service Info specification (see
above). The Service Registry specification is useful when dealing with
technologies that handle multiple GA4GH services. Common use
cases include creating networks or groups of services of a certain
type (e.g., Beacon Network searches networks of Beacon services
across multiple organizations, a workflow can be executed by a
specific group of Workflow Execution Services, or Data Connect
search on biomedical data is federated across a set of nodes), or a
certain host (e.g., an organization provides implementations of
Beacon, Data Connect, and Data Repository Service APIs, or a server
hosts an implementation of refget and htsget APIs).

Remotely run analytical methods on data of interest
samtools.github.io/htsspecs/htsget.html

API

API and tool developers,
researchers

htsget is a data retrieval API that bridges from existing genomics file
formats to a client/server model with the following features:
d Incumbent data formats (BAM, CRAM, VCF) are preferred
initially, with a future path to others.
d Multiple server implementations are supported, including those
that do format transcoding on the fly, and those that return
essentially unaltered filesystem data.
d Multiple use cases are supported, including access to small
subsets of genomic data (e.g., for browsing a given region) and
to full genomes (e.g., for calling variants).

refget13

samtools.github.io/htsspecs/refget.html

API

API and tool developers,
researchers

Refget (https://w3id.org/ga4gh/refget) is an API and mechanism for
generating identifiers for reference sequences and retrieving
sequences via API. The refget identifier is derived from sequence
content directly and therefore does not rely on a central issuing
authority. This allows downstream clients to unambiguously refer to a
reference sequence and to retrieve said sequence. The refget API can
also provide subsequences and metadata pertaining to the
checksum identifier. A refget server can host any number of reference
sequences of any type, e.g., genomic DNA or protein sequences. The
refget protocol is a fundamental building block of the CRAM
specification.
An OpenAPI description of this specification is available and
describes the 1.0.0 version (https://github.com/samtools/hts-specs/
blob/master/pub/refget-openapi.yaml). Implementors can check if
their refget implementations conform to the specification by using our
compliance suite (https://github.com/ga4gh/
refget-compliance-suite). A summary of all known public
implementations is available from our compliance report website.
(Continued on next page)
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Continued
URL
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Target user

Purpose

Task Execution
Service (TES)

https://github.com/ga4gh/
task-execution-schemas

API

API and tool developers,
researchers, academic
institutions

The Task Execution Service (TES) API is a standardized schema and
API for describing and executing batch execution tasks. A task
defines a set of input files, a set of containers and commands to run, a
set of output files, and some additional logging and metadata. TES
servers accept task documents and execute them asynchronously on
available compute resources. A TES server could be built on top of a
traditional HPC queuing system, such as Grid Engine, Slurm, or cloud
style compute systems such as AWS Batch or Kubernetes.

Tool Registry
Service (TRS)

https://github.com/ga4gh/
tool-registry-service-schemas

API

API and tool developers,
researchers, academic
institutions

The GA4GH Tool Registry (TRS) API aims to provide a standardized
way to describe the availability of tools and workflows. In this way,
multiple repositories that share Docker-based tools and workflows
(based on Common Workflow Language [CWL], Workflow
Description Language [WDL], Nextflow, or Galaxy) can consistently
interact, search, and retrieve information from one another. The end
goal is to make it much easier to share scientific tools and workflows,
enhancing our ability to make research reproducible, shareable, and
transparent.
To access the specification, users can:
d view the human-readable Reference Documentation
d explore the specification in the Swagger Editor
d preview documentation from the gh-openapi-docs for the
development branch at https://ga4gh.github.io/tool-registryservice-schemas/preview/develop/docs/index.html

Workflow
Execution
Service
(WES)

https://github.com/ga4gh/
workflow-execution-serviceschemas

API

API and tool developers,
researchers, academic
institutions

The Workflow Execution Service (WES) API describes a standard
programmatic way to run and manage workflows. Having this
standard API supported by multiple execution engines will let people
run the same workflow using various execution platforms running on
various clouds/environments. Key features include: (1) ability to
request a workflow run using CWL or WDL; (2) ability to parameterize
that workflow using a JSON schema; and (3) ability to get information
about running workflows.

Securely access genotype and phenotype information on patients with related traits
Authentication &
Authorisation
Infrastructure
(AAI)

https://github.com/ga4gh/
data-security/blob/master/
AAI/AAIConnectProfile.md

Guide

API and tool developers

(Continued on next page)

ll

The GA4GH Authentication & Authorisation Infrastructure (AAI)
specification profiles the OpenID Connect (OIDC) protocol to provide
a federated (multilateral) authentication and authorization
infrastructure for greater interoperability between genomics
institutions in a manner specifically applicable to (but not limited to)
the sharing of restricted datasets.
In particular, this specification introduces a JSON Web Token (JWT)
syntax for an access token to enable an OIDC provider (called a
Broker) to allow a downstream access token consumer (called a
Claim Clearinghouse) to locate the Broker’s /userinfo endpoint as a
means to fetch GA4GH Claims. This specification is suggested to be
used together with others that specify the syntax and semantics of the
GA4GH Claims exchanged.
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https://docs.google.com/
document/d/1cBTwtetnsv
O2vU3HVwLTLaC9H_ya4MjZUa_g_xzOBg/edit

Guide

anyone handling sensitive
data in a cloud infrastructure.

An increasing number of GA4GH projects rely on Cloud services to
pursue their goals, and the GA4GH Cloud Work Stream is working on
several products to make the GA4GH community take full advantage
of the Cloud paradigm. However, the use of the Cloud poses
significant security and privacy challenges that need to be carefully
evaluated and addressed. The purpose of the Cloud Security and
Privacy Policy is to outline a common security technology framework
that can be used to systematically assess the products developed by
the CWS from a security perspective. Product developers and
reviewers can leverage the information contained herein to identify
requirements, threats, and countermeasures related to the products
they are working on, thus facilitating the production of secure
standards.

CRAM14

samtools.github.io/htsspecs/CRAMv3.pdf

File Format

API and tool developers,
researchers

The CRAM file format holds DNA sequencing records. It has the
following major objectives:
d Significantly better lossless compression than BAM
d To permit simple and lossless transformations to and from BAM
files
d Support for controlled loss of data
The first two objectives allow users to take immediate advantage of
the CRAM format while offering a smooth transition path from using
BAM files.
The third objective supports the exploration of different lossy
compression strategies and provides a framework in which to effect
these choices.
Data in CRAM is stored in a columnar fashion, with each column being
compressed with either a general-purpose compressor or a custom
method. If aligned, sequences may be stored as differences against a
reference sequence, which is optionally stored within the CRAM file.
External references may be either a local file or obtained remotely via
the refget API. Data may be retrieved either as whole alignment
records, or selectively only for the fields (columns) required.
(Continued on next page)
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File Format

API and tool developers, data
generators, researchers,
clinicians, data custodians

By its nature, genomic data can include information of a confidential
nature about the health of individuals. It is important that such
information is not accidentally disclosed. One part of the defense
against such disclosure is to, as much as possible, keep the data in an
encrypted format. The Crypt4GH specification describes a file format
that can be used to store data in an encrypted state. Existing
applications can, with minimal modification, read and write data in the
encrypted format. The choice of encryption also allows the encrypted
data to be read starting from any location, facilitating indexed access
to files. The format has the following properties:
d Confidentiality: Data stored in the file are readable only by
holders of the correct secret decryption key. The format does
not hide the length of the encrypted file, although it is possible
to pad some file structures to obscure the length.
d Integrity: Data are stored in a series of 64 kilobyte blocks, each
of which includes a message authentication code (MAC). At
tempts to change the data in a block will make the MAC invalid;
it is not possible to recalculate the MAC without knowing the
key used to encrypt the file. The format only protects the
contents of each individual block. It does not protect against
insertion, removal, or reordering of entire blocks.
d Authentication: The format does not provide any way of
authenticating files.
Crypt4GH may be used with any data file or stream, but one usage is
encryption of BAM, CRAM, VCF, and BCF data within the htsget API
while still retaining full random access.

Data Repository
Service (DRS)

https://github.com/ga4gh/
data-repository-serviceschemas

API

API and tool developers,
researchers, academic
institutions

The Data Repository Service (DRS) API provides a generic interface to
data repositories so data consumers, including workflow systems,
can access data objects in a single, standard way regardless of where
they are stored and how they are managed. The primary functionality
of DRS is to map a logical ID to a means for physically retrieving the
data represented by the ID. The DRS specification describes the
characteristics of those IDs, the types of data supported, how they
can be pointed to using URIs, and how clients can use these URIs to
ultimately make successful DRS API requests. The specification also
describes the DRS API in detail and provides information on the
specific endpoints, request formats, and responses. This
specification is intended for developers of DRS-compatible services
and of clients that will call these DRS services.
(Continued on next page)
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https://github.com/ga4gh/
data-security/blob/
master/DSIP/DSIP_v4.0.md

Policy
Framework

data protection authorities

The Data Security Infrastructure Policy (DSIP) describes the data
security infrastructure recommended for stakeholders in the GA4GH
community. It is not meant to be a normative document, but rather a
set of recommendations and best practices to enable a secure data
sharing and processing ecosystem. However, it does not claim to be
exhaustive, and additional precautions other than the ones collected
in the policy might have to be taken to be compliant with national/
regional legislations. As a living document, the DSIP will be revised
and updated over time, in response to changes in the GA4GH Privacy
and Security Policy, and as technology and biomedical science
continue to advance.

Machine
Readable
Consent
Guidance
(MRCG) v1.0

https://www.ga4gh.org/wpcontent/uploads/Machinereadable-Consent-Guidance_
6JUL2020-1.pdf

Guide

researchers, institutional review
boards/research ethics
committees (international and
national), research ethics policy
makers, data generators,
funding agencies

The Machine Readable Consent Guidance (MRCG) provides
standardized consent clauses and supporting information to enable
the development of consent forms that map unambiguously to the
GA4GH Data Use Ontology (DUO). Integrating DUO into consent
forms thereby facilitates data discovery and data access requests
and approvals, maximizing data sharing, integration, and re-use while
respecting the autonomy of data subjects. MRCG implementations
include the Broad Data Use Oversight System (DUOS)16 and the
Australian Genomics dynamic consent participant platform, CTRL.

Pedigree V1

https://github.com/GA4GHPedigree-Standard/pedigree

Data Model /
Ontology

clinicians, researchers, API
and tool developers, data
generators, EHR vendors

Family health history is an important aspect in both genomic research
and patient care. The GA4GH pedigree standard is an object-oriented
graph-based model to represent family health history and pedigree
information. It is intended to fit within the structure of other standards
like HL7 FHIR and Phenopackets and enable the computable
exchange of family health history as well as representation of larger,
more complex families. Computable representation of family
structure will allow patients, physicians, and researchers to share this
information more easily between healthcare systems and help
software tools use this information to improve genomic analysis and
diagnosis. The draft model can be found on Github along with a
Family History Relations Ontology and draft FHIR implementation
guide. A draft recommendation for a minimal dataset of family health
history (https://docs.google.com/document/d/
1UAtSLBEQ_7ePRLvDPRpoFpiXnl6VQEJXL2eQByEmfGY/edit?
usp=sharing) was developed as a foundation of these efforts.
(Continued on next page)
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Phenopackets

http://phenopackets.org

Data Model /
Ontology

data generators, data
custodians, researchers,
clinicians, API and tool
developers

The Phenopacket specification is an open machine-readable schema
that supports the global exchange of disease and phenotype
information to improve our ability to diagnose and conduct research
on all types of diseases, including cancer and rare disease. A
Phenopacket links detailed phenotypic descriptions with disease,
patient, and genetic information, enabling clinicians, biologists, and
disease and drug researchers to build more complete models of
disease. Version 2 of the standard, released in June 2021, expands on
the previous version to include better representation of the time
course of disease, treatment, and COVID-19 and cancer-related data.
The schema, as well as source code in Java, C++, and Python, are
available from the phenopacket-schema GitHub repository.

RNAget

https://ga4gh-rnaseq.github.
io/schema/docs/index.html

API

Data generators, data
custodians, researchers,
tool developers

The RNAget API describes a common set of endpoints for search and
retrieval of processed RNA data. This currently includes feature level
expression data from RNA-seq type assays and signal data over a
range of bases from ChIP-seq, methylation, or similar epigenetic
experiments.
By using these common endpoints, data providers make it easier for
client software to access their data with minimal or no modifications
to underlying code. This improves interoperability with other
compliant data providers and makes it easier for investigators to
retrieve and compare data from multiple sites.
For the software developer, these common endpoints and patterns
make it easier to access multiple compliant server sites with the same
client software. This reduces development time which may have
otherwise been spent writing parsers and custom request generators.
Using the API, it becomes much easier to write software to conduct
comparisons, data mingling, or other analyses on data retrieved from
multiple, potentially geographically dispersed data servers.
The OpenAPI description of the specification can be used with code
generators like OpenAPI Generator. The testing and compliance page
includes a list of example server implementations which can be used
as is or as a starting point. A custom solution can be implemented to
link the API endpoints and queries to a local data backend (of any
desired type) serving the data.
(Continued on next page)
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samtools.github.io/hts-specs/
SAMv1.pdf

File Format

researchers

SAM, or Sequence Alignment/Map format, is a format for storing
primary DNA sequencing records. These are typically aligned and
sorted by genomic coordinate, but unaligned data can also be
represented. SAM is a TAB-delimited text format consisting of a
header meta-data section and an alignment section. The BAM format
is a binary serialization of SAM for more efficient access. SAM and
BAM support full random access, selected by genomic region. The
SAMtags document defines the optional per-record annotations.
These are also used by the CRAM specification.

Variant Annotation

https://github.com/ga4gh/
va-spec

Data Model /
Modeling
Framework

API and tool developers

Variant annotations are structured data object that holds a central
piece of knowledge about a genetic variation, along with metadata
supporting its interpretation and use. A given variant annotation may
describe knowledge about its molecular consequence, functional
impact on gene function, population frequency, pathogenicity for a
given disease, or impact on therapeutic response to a particular
treatment. The GA4GH VA-Specification will define an extensible data
model for representation and exchange these and other diverse kinds
of variant annotations. It will provide machine-readable messaging
specifications to support sharing and validation of data through APIs
and other exchange mechanisms. It will also provide a formal
framework for defining custom extensions to the core model allowing community-driven development of VA-based data models
for new data types and use cases. A more detailed description of
these components can be found online.
The VA-Spec is being authored by a partnership among national
resource providers and major public initiatives within GA4GH. It has
been informed by and will be tested in diverse, established, and
actively developed Driver Projects, including ClinGen, VICC,
Genomics England, the Monarch Initiative, BRCA Exchange, and
Australian Genomics. In these contexts, it will be used to support
different types of tools and information systems, including variant
curation tools and interpretation platforms (e.g., ClinGen, CIViC,
Genomics England), variant annotation services (e.g., CellBase),
knowledge aggregators/portals (e.g., BRCA Exchange, Monarch
Initiative), matchmaking applications (e.g., Matchmaker Exchange),
and clinical information systems and decision support tools.
(Continued on next page)
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https://vrs.ga4gh.org

Data Model &
terminology

data generators, API and
tool developers, data
custodians

Maximizing the personal, public, research, and clinical value of
genomic information will require that clinicians, researchers, and
testing laboratories exchange genetic variation data reliably. The
Variation Representation Specification (VRS, pronounced ‘‘verse’’) —
written by a partnership among national information resource
providers, major public initiatives, and diagnostic testing
laboratories — is an open specification to standardize the exchange
of variation data.
The primary contributions of VRS include (1) terminology and an
information model, (2) a machine readable schema, (3) conventions
that promote reliable data sharing, (4) globally unique computed
identifiers, and (5) a Python implementation (available at vrs-python)
that demonstrates the above schema and algorithms and supports
translation of existing variant representation schemes into VRS for
use in genomic data sharing. It may be used as the basis for
development in Python, but it is not required in order to use VRS.
The machine-readable schema definitions and example code are
available online at the VRS repository. Readers may wish to view a
complete example before reading the specification. For a discussion
of VRS with respect to existing standards, such as HGVS, SPDI, and
VCF, see ‘‘Relationship of VRS to existing standards,’’ an appendix to
the specification documentation.

VCF/BCF19

samtools.github.io/htsspecs/VCFv4.3.pdf

File Format

researchers

The variant call format (VCF) is a generic format for storing DNA
polymorphism data such as single nucleotide polymorphisms (SNPs),
insertions, deletions, and structural variants, together with rich
annotations. VCF may hold data for multiple samples within the same
file. The specification contains the header meta-data fields, a series of
mandatory columns describing the variants, and details of the
optional annotations which are either per-site or per-sample. VCF and
its binary counterpart, BCF, is usually stored in a compressed manner
and can be indexed for fast data retrieval of variants from a range of
positions on the reference genome.

The GA4GH Toolkit outlines a suite of secure standards and frameworks that will enable more meaningful research and patient data harmonization and sharing. This suite addresses a variety of
challenges across the data sharing life cycle and is applicable across the world’s accessible medical and patient-centered systems, knowledgebases, and raw data sources. All standards are
subject to the GA4GH Copyright Policy (https://www.ga4gh.org/wp-content/uploads/GA4GH-Copyright-Policy-Updated-Formatting.pdf) and should be made available under an open source
license such as the Apache 2.0 license for software.
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URL

Variation
Representation18

Perspective

Table 1.

Location

Current size

Data type(s) collected

All of Us Research
Program

https://allofus.nih.gov/

US

RD, Ca, CT

100k whole-genome
sequences (planning
for 1 million)

WGS, WES

centralized

cloud

CRAM, DRS (forthcoming),
htsget (forthcoming),
Passports (forthcoming),
TRS (forthcoming), and
WES (forthcoming)

Australian
Genomics

https://www.australian
genomics.org.au/

Australia

RD, Ca, CT

13,500 whole-genome
sequences across
all pilots

WGS, WES, panels,
phenotype

centralized

cloud

Beacon V1, CRAM,
Crypt4GH, DRS
(forthcoming), DUO,
htsget, MRCG
(forthcoming), Passports
(forthcoming), refget

Autism Sharing
Initiative

https://www.autism
sharinginitiative.org/

international CT

11,316 whole-genome
sequences (estimating
15k by 2025)

WGS

distributed

federated
analysis

AAI (forthcoming), Beacon
V1 (forthcoming), CRAM
(forthcoming), Data Connect,
DRS (forthcoming), DUO
(forthcoming), Passports
(forthcoming), Service
Registry / Info, TRS
(forthcoming), WES
(forthcoming)

BRCA Exchange

http://www.brca
exchange.org

international RD, Ca

66,657 variants

genetic variant
pathogenicity
assertions and
supporting
evidence

centralized

public

Beacon V1, VA
(forthcoming), VRS,
WES (forthcoming)

CanDIG

https://www.distributed Canada
genomics.ca/

RD, Ca, CT, 1,700 data records
Bio

WGS tumor/normal
and whole
transcriptome
for cancer; WGS for
COVID; clinical
phenotype

distributed

federated
analysis

Beacon V1, CRAM, DRS,
DUO, htsget, Phenopackets,
refget (forthcoming),
RNAGet, Service Registry /
Info (forthcoming), VRS
(forthcoming), WES
(forthcoming)

ClinGen

https://www.clinical
genome.org/

RD

genetic and
experimental
evidence

centralized

public

VA (forthcoming), VRS

US

2,077 unique genes
with at least one
curation and 2,417
unique variants with
at least one curation

(Continued on next page)
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Table 2. GA4GH Driver Projects

Continued
Thematic
area*

URL

Location

https://elixir-europe.
org/

Europe

RD, Ca,
CT, Bio

23 national nodes
hold a variety of data
types and run
multiple services,
some listed within
this table (e.g., EGA).
For a list of ELIXIR
Core Data Resources,
see https://elixir-europe.
org/platforms/data/
core-data-resources

Current size

ENA / EVA / EGA

https://www.ebi.
ac.uk/ena,

Europe

RD, Ca,
CT, Bio

EGA - 700k data
records

EpiShare

https://epishareproject.org/

international Bio

EUCANCan

http://www.eucancan.
com

European Joint
Programme
on Rare Disease
(EJP RD)

https://www.ejprare
diseases.org/

Data type(s) collected

download
(also
exploring
Cloud)

AAI, Beacon V1, Crypt4GH,
DRS, DUO, htsget, Passports,
Phenopackets, refget,
RNAGet, Service Registry /
Info, TES, TRS, WES

EGA - WGS, WES,
RNaseq, epigenetics,
genotyping,
transcriptome, singlecell seq, healthy
and disease cohorts

distributed

download
(also
exploring
Distributed
Cloud)

Crypt4GH, htsget AAI,
Passports, DUO

2,800 data records

FASTQ, CRAM/BAM,
bigwig, bigbed for
epigenomics
experiments

distributed

federated
analysis

CRAM (forthcoming), DRS,
DUO, htsget (forthcoming),
Phenopackets, RNAGet,
Service Registry / Info, WES

international Ca

data from 35 different
sources including
human, model, and
non-model organisms

whole-genome, wholeexome, and wholetranscriptome
sequence data

distributed

Cloud and
federated
analysis

AAI (forthcoming), Beacon
V1 (forthcoming), CRAM
(forthcoming), Data Connect
(forthcoming), DRS
(forthcoming), Passports
(forthcoming), Phenopackets
(forthcoming), Service
Registry / Info (forthcoming),
TES (forthcoming), TRS
(forthcoming), VRS
(forthcoming), WES
(forthcoming)

Europe

>130,000 data records
across several
resources hosting
genomic human data,
mainly the EGA,
DECIPHER and the
RD-Connect GenomePhenome Analysis
Platform

a mix of WGS, WES,
plausibly pathogenic
variants and
phenotypic
information

distributed
across
centralized
resources

download
and Cloud
analysis

AAI (forthcoming), Beacon
V1, CRAM, Crypt4GH, DRS
(forthcoming), DUO, htsget,
Passports, Phenopackets,
Service Registry / Info,
TES, TRS, WES

RD

(Continued on next page)
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Implementations /
Data hosting Data access deployments of
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GA4GH standards

Perspective

Table 2.

Continued

Driver Project

URL

Location

Current size

Data type(s) collected

GEnome Medical
Alliance Japan
(GEM Japan)

https://www.amed.go.
jp/en/aboutus/
collaboration/ga4gh_
gem_japan.html

Japan

RD, Ca, CT

24k WGS (aiming for
100k)

whole-genome
sequencing, wholeexome sequencing,
gene expression,
panels, phenotypic

centralized

download
(also
exploring
Cloud)

Beacon V1 (forthcoming),
CRAM, DUO, Phenopackets
(forthcoming)

Genomics England

https://www.genomics
england.co.uk

UK

RD, Ca, CT

136K WGS,
(estimating 450K
WGS by 2024)

WGS

centralized

Cloud

AAI (forthcoming), CRAM,
DRS (forthcoming), DUO
(forthcoming), htsget,
Passports (forthcoming),
WES (forthcoming)

Human Cell Atlas

https://www.human
cellatlas.org

International RD, Ca,
CT, Bio

1,300 donors

single-cell sequencing

centralized

public and
Cloud

AAI, DRS, DUO (forthcoming),
Passports (forthcoming),
TES, TRS, WES

Human Heredity
and Health
in Africa (H3Africa)

https://h3africa.org/

Africa

75,000 participants
(across all projects)

whole-genome
sequencing, wholeexome sequencing,
gene expression,
microbiome,
imaging, phenotypic,
environmental/lifestyle

centralized

download

AAI (forthcoming), Beacon
V1, CRAM, Crypt4GH, Data
Connect (forthcoming),
DUO, Passports
(forthcoming), Phenopackets
(forthcoming), VRS
(forthcoming)

CT, Bio

international Ca

100k Genomes

WGS, WES, RNA-Seq,
phenotype

distributed

Cloud and
federated
analysis

AAI (forthcoming), Beacon
V1, CRAM, Passports
(forthcoming), TRS, WES

Matchmaker
Exchange

https://www.match
makerexchange.org

international RD

>109K cases

WGS, WES

distributed

federated
analysis

AAI (forthcoming), Beacon
V1, CRAM, htsget,
Phenopackets

Monarch Initiative

https://monarch
initiative.org/

international RD, Ca,
CT, Bio

N/A

gene, genotype,
variant, disease, and
phenotype data across
many species in the
tree of life, from over
30 data sources

centralized

public cloud DUO (forthcoming),
Passports (forthcoming),
Phenopackets, VRS

National Cancer
Institute Cancer
Research Data
Commons (NCI
CRDC)

https://datascience.
cancer.gov/datacommons

US

100,000 data records whole-genome
(includes GDC)
sequencing, wholeexome sequencing,
gene expression,
panels, phenotypic,
biospecimen,
imaging, proteomics

centralized

Cloud and
federated
analysis

Ca

CRAM, DRS, DUO
(forthcoming), Passports
(forthcoming), Service
Registry / Info, WES

(Continued on next page)

Perspective

International Cancer https://www.icgcGenome Consortium argo.org
(ICGC) Accelerating
Research in Genomic
Oncology (ARGO)
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Table 2.

Continued
Implementations /
Data hosting Data access deployments of
model(s)
model(s)
GA4GH standards

URL

Location

Current size

Data type(s) collected

National Cancer
Institute Genomic
Data Commons
(NCI GDC)

https://gdc.cancer.gov

US

Ca

83,700 cases

centralized
WGS, WXS, panel,
RNA-seq, miRNA-seq,
methylation array,
genotyping array,
diagnosis slides, tissue
slides, ATAC-seq,
scRNA-seq. Also
clinical (phenotypic)
and biospecimen
information

download
and Cloud

AAI (forthcoming), CRAM
(forthcoming), DRS
(forthcoming), DUO
(forthcoming), Passports
(forthcoming), Phenopackets
(forthcoming), TES
(forthcoming), TRS
(forthcoming), VRS
(forthcoming), WES
(forthcoming)

Swiss Personalized
Health Network
(SPHN)

http://sphn.ch

Switzerland

RD, Ca,
CT, Bio

24 health data
projects across
Switzerland

distributed
clinical phenotypic,
clinical routine,
omics (genomic,
transcriptomic,
proteomic, etc), cohort,
and imaging data and
expert variant curation

federated
analysis

Beacon V1, DRS
(forthcoming), htsget
(forthcoming),
Phenopackets, TES
(forthcoming), WES
(forthcoming)

Trans-Omics for
Precision Medicine
(TOPMed)

https://topmed.
nhlbi.nih.gov

US

RD, Ca,
CT, Bio

180k whole genome
sequences (233k
by 2025), 96k panels

centralized
WGS, RNA-seq,
metabolome,
methylome
(MethylationEPIC
‘850K’), proteome
(SomaScan
and Olink), longitudinal
epidemiology studies,
disease-studies,
environmental/ lifestyle,
imaging

cloud

AAI (forthcoming), CRAM,
DRS, DUO, Passports
(forthcoming), Service
Registry / Info
(forthcoming), TRS, WES

Variant Interpretation
for Cancer
Consortium (VICC)

cancervariants.org

international Ca

24,366 evidence
items

genetic and
experimental
evidence

centralized

public

Beacon V1, Service
Registry / Info, VA
(forthcoming), VRS

GA4GH Driver Projects are external genomic data initiatives that have committed to both contributing to the development of genomic data sharing standards as well as piloting their use in real
world practice. Abbreviations: RD, rare disease; Ca, cancer; CT, complex traits; Bio, basic biology.
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20https://raw.githubusercontent.com/ga4gh-discovery/ga4gh-serviceinfo/develop/service-info.yaml
GA4GH Variant Annotation repository, https://github.com/ga4gh/va-spec
GA4GH Variation Representation Specification (VRS), https://vrs.ga4gh.
org/en/stable/
GA4GH VRS example, https://vrs.ga4gh.org/en/stable/impl-guide/
example.html#example
GA4GH VRS Python implementation, https://github.com/ga4gh/
vrs-python/
GA4GH VRS relationship to existing standards: https://vrs.ga4gh.org/en/
stable/appendices/relationships.html#relationships
GA4GH VRS repository, https://github.com/ga4gh/vrs
GA4GH Workflow Execution Service (WES) API, https://github.com/
ga4gh/workflow-execution-service-schemas
GEnome Medical Alliance Japan (GEM Japan), https://www.amed.go.jp/
en/aboutus/collaboration/ga4gh_gem_japan.html
Genomics England, https://www.genomicsengland.co.uk/
gnomAD, https://gnomad.broadinstitute.org/
Health Level Seven (HL7), http://www.hl7.org/
HL7 genomics reporting implementation guide, http://hl7.org/fhir/uv/
genomics-reporting
Htsget, https://samtools.github.io/hts-specs/htsget.html
Human Cell Atlas, https://www.humancellatlas.org/
Human Heredity and Health in Africa (H3Africa), https://h3africa.org/
International Cancer Genome Consortium (ICGC) Accelerating Research
in Genomic Oncology (ARGO), https://www.icgc-argo.org/
International COVID-19 Data Alliance (ICODA), https://icoda-research.org/
International Organization for Standardization (ISO), https://www.iso.org/
home.html
Internet Engineering Task Force (IETF), https://www.ietf.org/
Matchmaker Exchange, https://www.matchmakerexchange.org/
Monarch Initiative, https://monarchinitiative.org/
National Cancer Institute Genomic Data Commons (NCI GDC), https://
gdc.cancer.gov/
National Cancer Institute Cancer Research Data Commons (NCI CRDC),
https://datascience.cancer.gov/data-commons
NIH policy for data management and sharing, https://grants.nih.gov/
grants/guide/notice-files/NOT-OD-21-013.html
Open Biological and Biomedical Ontology Foundry (OBO): obofoundry.org/
OpenAPI description of refget v1.0.0, https://github.com/samtools/
hts-specs/blob/master/pub/refget-openapi.yaml
Phenopackets, http://phenopackets.org/
Phenopackets GitHub repository, https://github.com/phenopackets/
phenopacket-schema
PLINK, http://zzz.bwh.harvard.edu/plink/data.shtml
Public Health Alliance for Genomic Epidemiology (PHA4GE), https://
pha4ge.org/
Refget documentation, https://samtools.github.io/hts-specs/refget.html
Refget summary public implementations, https://andrewyatz.github.io/
refget-compliance/
Rare disease consent clauses, https://bmcmedethics.biomedcentral.
com/articles/10.1186/s12910-019-0390-x/tables/3
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SAM (Sequence Alignment/Map) file format, https://samtools.github.io/
hts-specs/SAMtags.pdf
Service registry, https://github.com/ga4gh-discovery/ga4gh-serviceregistry
Swiss Personalized Health Network (SPHN), https://sphn.ch/
Variant call format (VCF), https://samtools.github.io/hts-specs/VCFv4.3.
pdf
Trans-Omics for Precision Medicine (TOPMed), https://topmed.nhlbi.nih.
gov/
The Task Execution Service (TES) API, https://github.com/ga4gh/
task-execution-schemas
TRS human-readable Reference Documentation, https://ga4gh.github.io/
tool-registry-service-schemas/
Variant Interpretation for Cancer Consortium (VICC), https://
cancervariants.org/
Variant Annotation proposal, https://docs.google.com/document/d/
1q8P1bjVyyslLcV8Gw_hXDc9JzOSuNbJyts-QDx1F17s/edit#heading=h.
3e4s876j01gp
World Wide Web Consortium (W3C), https://www.w3.org/
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Introduction
This document outlines the processes by which the Global Alliance for Genomics and Health
(GA4GH) develops and certiﬁes technical standards and policy frameworks emerging from its
work streams (WSs). GA4GH intentionally does not prescribe an in-depth and strict set of do’s
and don'ts. Each product comes with its own community and working practices. To enforce the
same working practice across all products would be counterproductive and only increase the
administrative burden of initiating new work or bringing external products into GA4GH. However,
the organization does require that teams meet two speciﬁc milestones:
1) Proposal: before work on a new deliverable begins, the relevant Work Stream must
present a proposal to the GA4GH Steering Committee, outlining the scope and expected
impact of the new deliverable and the stakeholders that will be involved / aﬀected.
2) Approval: before a new major version of a deliverable is released, it is submitted for
approval and undergoes review by GA4GH committees as outlined below.

Product Proposal Process
Products are proposed and developed in response to the needs of the GA4GH Driver Projects
(DPs)—real world genomic data initiatives that have committed to contributing to GA4GH
standards development and implementation—or the wider genomics and health community. To
maximize return on eﬀort, WSLs prioritize development based on the number of requesting
sources, leading to a limited number of deliverables with a greater adoption potential. WSs are

encouraged to include a broad landscape analysis in their initial prototyping activities; the
speciﬁc details of this exercise is left to the discretion of the WSLs.
If WSLs decide to formally develop an initial prototype into a completed product, they work with
the WS Manager (WSM) to create a Product Proposal slide deck to present to the GA4GH
Steering Committee (SC). The groups that explicitly request a product are considered the “source
projects” for that product. Each proposed product must be associated with at least two source
projects. The product proposal deck and presentation at SC serves to notify other WSLs as well
as DP Champions (DPCs) of the nature of the product being developed and to identify potential
areas of overlap. In conjunction with the Product Proposal deck, the WSM also supports the team
in completing the Data Security Product Proposal Questionnaire (reviewed by the Data Security
Work Stream [DSWS] to ensure relevant security risks are considered) and the Regulatory and
Ethics Questionnaire (reviewed by the Regulatory and Ethics Work Streams [REWS]). If signiﬁcant
issues are raised by anyone on SC or during the DSWS or REWS reviews, amendments may be
made to the initial Product Proposal. Following these actions, the product is incorporated into the
GA4GH Roadmap.

Development Process
GA4GH consists of eight WSs—two foundational and six technical. Foundational Work Streams
provide guidance across GA4GH in the areas of regulation, ethics, and data security in genomics.
Technical Work Streams develop GA4GH’s technical standards and consist of leaders in their
respective sub-disciplines from around the world. Technical WSs work to both discover and
harden existing “working standards” and to create entirely new standards where needed. WS
membership is voluntary and open to anyone. GA4GH welcomes additional interested individuals
and organizations and encourages them to actively contribute across the organization by
subscribing to emails, joining teleconferences, and attending face-to-face meetings.
GA4GH Subgroups are established within WSs to provide a focused space to develop and
maintain speciﬁc deliverables. These groups also serve to guide future development activities
and eﬀorts to integrate the deliverable with other GA4GH products. Integration eﬀorts also make
use of Driver Projects, the Technical Alignment Subcommittee (TASC), and the Federated Analysis
Systems Project (FASP) as ways of aligning and integrating deliverables.
Development work is carried out publicly and may use a system capable of tracking requests for
changes, authorship, and history. In general, work such as program code, schemas, and
documentation takes place in GitHub or Google Drive. Each WS and subgroup may have a
unique approach to accepting changes, additions, and revisions to a standard, although most will
recommend these be requested on GitHub trackers beginning with a pull request. See the
GA4GH How We Work document for more details on the development process.
GA4GH speciﬁcations should meet the requirements of the source Driver Projects which
requested them, or have had some feedback from the community in which it is intended to be
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used. Development teams are encouraged to consider RFC 7282 from the Internet Engineering
Task Force (IETF) to guide the decision making process.
Foundational Work Streams are contacted with Security, Regulatory, or Ethical concerns that arise
during the development process.

Product Approval Process
When product leads and WSLs feel a GA4GH product is ready for a major version release, it is
Submitted for Approval using the GA4GH Product Approval Submission Form. The GA4GH
secretariat then notiﬁes SC, as well as DSWS and REWS, which review the completed product
using the DSWS and REWS review questionnaires. A Product Review Committee (PRC) is
assembled, consisting of three members nominated by the submitter: (i) WSL from a diﬀerent
TWS, (ii) a member of a third Technical WS, and (iii) a representative from one of the product’s
source DPs.
The review committee may give a response of “Accept”, “Reject”, or “Changes Requested”. All
three members must agree unanimously for the committee to give a positive assessment. The
committee should deliver their response one month after the speciﬁcation is submitted.
If one of the three review bodies (REWS, DSWS, PRC) does not unanimously approve the product,
requested upgrades will be communicated to the submitting WSMs. An upgraded product can be
sent to the reviewers directly. This cycle can be repeated until the product passes the review
body requirements.
Once all three bodies have approved the product, it is sent to the GA4GH SC for Approval. This
must be done two weeks prior to the Steering Committee meeting at which it is to be assessed.
At the SC meeting, one WSL presents the product and the PRC may be called upon to explain the
PRC decision. If SC votes unanimously to approve the product it becomes an Approved GA4GH
Deliverable. If one or more SC members reject the product, the product may be required to make
changes and then re-submit as described above. If the issues are minor enough. to allow the
product to be re-considered in a single expedited review.

Approving New Versions
Minor and Patch updates to GA4GH products may take place without the Product Review
Committee being re-convened. The approval of a new major version requires a new Product
Approval submission, as described above.

Implementations
Each speciﬁcation should have at least two associated implementations. These do not need to be
oﬃcially maintained reference implementations. For a client-server model there should be at
least two server deployments on separate implementation code bases interoperating
successfully with two clients. These are viewed as best eﬀorts and viewed as a way to ensure a
robust product is developed. These implementations are not written or managed by WSs, but
3/4

rather by the Driver Projects and the community. Ideally, they are real world implementations of
standards inside real-world environments that use real-world data. WSs facilitate interoperability
testing between these implementations, which may lead to speciﬁcation updates.
The Federated Analysis Systems Project (FASP) is a cross-WS initiative that aims to show that
GA4GH APIs, when used in concert, can facilitate real-world, scientiﬁc use cases by conducting
genomic analysis in the cloud. FASP aims to simulate how a researcher would search, access,
and analyze genomic data within the GA4GH ecosystem via end-to-end test scenarios involving
multiple Driver Projects. The FASP team also runs test scenarios against a wide variety of web
service implementations, showing that common API speciﬁcations facilitate interoperability. This
work involves the development of a comprehensive list of scientiﬁc use cases, as well as new
web services for the test scenarios to run against. Learnings from FASP test scenarios are also
fed back to the WSs and may lead to additional speciﬁcation updates.

Retirement Process
WSLs may retire a product by submitting a request using the GA4GH Product Retirement Form.
Any attribution or mention of GA4GH will be removed if appropriate. Products will be updated to
point to their replacement if they have been superseded by a newer GA4GH Approved Product.
GA4GH may choose to fork a product if the Secretariat deem a need to.

Glossary
●
●
●
●
●
●
●
●
●
●
●
●

DP = Driver Project
DPC = Driver Project Champion
DSWS = Data Security Work Stream
FASP = Federated Analysis Systems Project
IETF = Internet Engineering Task Force
PRC = Product Review Committee
REWS = Regulatory & Ethics Work Stream
SC = Steering Committee
TASC = Technical Alignment Sub-Committee
WS = Work Stream
WSL = Work Stream Lead
WSM = Work Stream Manager
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